(Q58375648)

inferred from title

author

Erica Ollmann Saphire

object named as

Erica Ollmann Saphire

1

0 references

Bronwyn M Gunn

3

object named as

Bronwyn M. Gunn

0 references

Galit Alter

5

object named as

Galit Alter

0 references

author name string

Sharon L. Schendel

2

0 references

Jacob C. Milligan

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

4

0 references

language of work or name

English

0 references

publication date

17 October 2018

0 references

November 2018

0 references

published in

Nature Immunology

0 references

volume

19

0 references

issue

11

0 references

page(s)

1169-1178

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antibody therapies for the prevention and treatment of viral infections.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Beyond binding: antibody effector functions in infectious diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antibody-based therapies for emerging infectious diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Swift antibodies to counter emerging viruses

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Harnessing Fc receptor biology in the design of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Correlative microscopy for structural microbiology.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Role of Fc-mediated antibody function in protective immunity against HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Ebola virus can be effectively neutralized by antibody produced in natural human infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structures of protective antibodies reveal sites of vulnerability on Ebola virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Epitopes involved in antibody-mediated protection from Ebola virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The impact of glycosylation on the biological function and structure of human immunoglobulins.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Glycosylation of recombinant antibody therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Advances in the assessment and control of the effector functions of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Production of therapeutic antibodies with controlled fucosylation

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

How to turn competitors into collaborators

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Generation of biologically contained Ebola viruses

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Systems serology for evaluation of HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

CD107a as a functional marker for the identification of natural killer cell activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Mechanism of human antibody-mediated neutralization of Marburg virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structural basis for Marburg virus neutralization by a cross-reactive human antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Ebola virus entry requires the host-programmed recognition of an intracellular receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structural basis of potent Zika–dengue virus antibody cross-neutralization

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antibody responses to envelope glycoproteins in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Mouse model recapitulating human Fcγ receptor structural and functional diversity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Fcgamma receptors as regulators of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Considering aspects of the 3Rs principles within experimental animal biology.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Isotype and glycoform selection for antibody therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Fc receptor but not complement binding is important in antibody protection against HIV.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Biological significance of carbohydrate chains on monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Marketing approval of mogamulizumab: a triumph for glyco-engineering

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Engineered antibody Fc variants with enhanced effector function

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Complement is activated by IgG hexamers assembled at the cell surface

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Beyond Viral Neutralization

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Immune correlates of vaccine protection against HIV-1 acquisition

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Complex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light Chain

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0233-9

7 January 2021

GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies

1 reference

12 December 2020

Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies

1 reference

12 December 2020

humanized mice to study FcγR function

1 reference

12 December 2020

Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer

1 reference

12 December 2020

Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus

1 reference

12 December 2020

Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection

1 reference

12 December 2020